Novartis halts CAR T therapy trials after patient deaths
Novartis halted clinical trials for its CAR T therapy rapcabtagene autoleucel after three patient deaths due to severe immune reactions. Bristol Myers Squibb also paused trials for its competitor product zola-cel, citing reversible inflammatory events. Both therapies target CD19, a protein linked to immune responses, but can cause severe immune reactions. Neither company has identified a cause.
How this was made
The 30-second read
Why it matters
The halts introduce uncertainty around timelines for autoimmune disease indications and may affect upcoming earnings guidance.
Market read
Both stocks could see short‑term downside as investors reassess risk, with possible ripple effects across the CAR‑T sector.
What to watch
Potential for accelerated safety protocol improvements and alternative targets beyond CD19.
Background
Novartis and BMS announced voluntary pauses in their CAR‑T trials after patient deaths linked to severe immune reactions.
Ticker impact
Novartis halted its CAR T therapy trials after three patient deaths.
Potential short-term sell pressure on NVS.
Safety concerns in a late‑stage program typically depress stock until clarity is provided.
Bristol Myers Squibb also suspended its zola‑cel CAR T trials following similar inflammatory events.
Likely downward pressure on BMY shares.
Parallel trial halts suggest sector‑wide risk for CD19 CAR‑T candidates.
Market effects
Biotech sector may see broader risk reassessment for CAR‑T programs.
European and US biotech markets could experience modest pullbacks.
Global investors tracking immunotherapy pipelines will monitor regulatory responses.
Counterpoint
If the events are isolated, the pause could be brief and the long‑term upside remains.
Key entities
- CompanyNovartis
Global pharma developer of rap‑cel CAR‑T therapy.
- CompanyBristol Myers Squibb
Developer of zola‑cel CAR‑T therapy.
